Academic
Publications
Pathological complete response induced by first-line chemotherapy with single agent docetaxel in a patient with advanced non small cell lung cancer

Pathological complete response induced by first-line chemotherapy with single agent docetaxel in a patient with advanced non small cell lung cancer,10

Pathological complete response induced by first-line chemotherapy with single agent docetaxel in a patient with advanced non small cell lung cancer   (Citations: 1)
BibTex | RIS | RefWorks Download
BACKGROUND: Defining the optimal treatment for patients with inoperable non small cell lung cancer (NSCLC), presenting with metastatic mediastinal lymph nodes, is challenging. Nevertheless, preoperative chemotherapy or radiotherapy might offer a chance for these patients for radical surgical resection and, possibly, complete recovery. CASE PRESENTATION: A 62-year old man with IIIA-N2 inoperable NSCLC was treated with first-line single agent docetaxel. A platinum-based treatment, though considered more active, was ruled out because of renal impairment. The patient tolerated the treatment very well and, although his initial response was not impressive, after 14 cycles he obtained a complete clinical response, which was confirmed pathologically after he underwent surgical lobectomy. CONCLUSION: In non-operable NSCLC patients not eligible for a platinum-based treatment, single-agent docetaxel can provide complete pathologic responses. Failure to obtain a response after the first few cycles should not automatically discourage to continue treatment.
Journal: World Journal of Surgical Oncology - WORLD J SURG ONCOL , vol. 8, no. 1, pp. 8-4, 2010
Cumulative Annual
View Publication
The following links allow you to view full publications. These links are maintained by other sources not affiliated with Microsoft Academic Search.
    • ...Docetaxel was found to be a mitotic spindle poison that stabilizes microtubules and inhibits their depolymerization to free tubulin, leading to a mitotic block in proliferating cells, and has a proven significant activity against NSCLC and gastric cancer [4, 5]. This agent is predominantly eliminated by hepatobiliary excretion and renal excretion is minimal [6‐8]...
    • ...Docetaxel is safe in patients with renal failure, including dialysis patients [8, 13, 14], and in addition, a very low incidence of acute renal failure associated with docetaxel (less than 0.1%) has been reported (summary of product characteristics from Sanofi Aventis Co. Ltd.)...

    Takayuki Takimotoet al. Tubular nephrotoxicity induced by docetaxel in non-small-cell lung can...

Sort by: